share_log

CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Patel Naimish

CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Patel Naimish

CRISPR Therapeutics | 3：首次持股聲明-高管 Patel Naimish
美股sec公告 ·  05/29 10:31
牛牛AI助理已提取核心訊息
CRISPR Therapeutics AG, represented by Naimish Patel, the company's Chief Medical Officer, has filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 28, 2024. The Form 3 filing indicates that Patel does not beneficially own any non-derivative or derivative securities of CRISPR Therapeutics. This standard disclosure is required under Section 16(a) of the Securities Exchange Act of 1934 and is a routine filing for officers of publicly traded companies to report securities holdings and transactions to the SEC.
CRISPR Therapeutics AG, represented by Naimish Patel, the company's Chief Medical Officer, has filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 28, 2024. The Form 3 filing indicates that Patel does not beneficially own any non-derivative or derivative securities of CRISPR Therapeutics. This standard disclosure is required under Section 16(a) of the Securities Exchange Act of 1934 and is a routine filing for officers of publicly traded companies to report securities holdings and transactions to the SEC.
由該公司首席醫療官奈米什·帕特爾代表的CRISPR Therapeutics AG已於2024年5月28日向美國證券交易委員會提交了初步的證券實益所有權聲明。表格3文件表明，帕特爾不以實益方式擁有CRISPR Therapeutics的任何非衍生或衍生證券。該標準披露是1934年《證券交易法》第16（a）條所要求的，是上市公司高管向美國證券交易委員會報告證券持有和交易的例行文件。
由該公司首席醫療官奈米什·帕特爾代表的CRISPR Therapeutics AG已於2024年5月28日向美國證券交易委員會提交了初步的證券實益所有權聲明。表格3文件表明，帕特爾不以實益方式擁有CRISPR Therapeutics的任何非衍生或衍生證券。該標準披露是1934年《證券交易法》第16（a）條所要求的，是上市公司高管向美國證券交易委員會報告證券持有和交易的例行文件。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。